Triazavirin, 250 mg capsules 20 pcs

Antiviral agent.

ATX code: J05AX.

Pharmacological properties

Pharmacodynamics

The active substance of the drug TRIAZAVIRIN

sup>® – riamilovir is a synthetic analog of purine nucleoside bases (guanine) with expressed antiviral action. It has a broad spectrum of antiviral activity against RNA-containing viruses.

The basic mechanism of action of the preparation TRIAZAVIRIN ^® is inhibition of synthesis of viral RNA and replication of genomic fragments.

Pharmacokinetics

After oral administration, it is rapidly absorbed in the gastrointestinal tract. Maximum concentration (C_max) is reached on average in 1-1.5 h. C_max with the recommended dosing regimen is on average 4.8 µg/ml. Blood AUC (area under the pharmacokinetic curve “concentration – time”) is 12.8 µg/h*ml. The elimination half-life (T_1/2) is 1-1.5 h. 15 to 45% of riamilovir is excreted unchanged by the kidneys. The average value of estimated clearance is 246 ml/min.

Indications

Influenza As part of the complex therapy of influenza and other acute respiratory viral infections in adult patients.

Active ingredient

Sodium methylthionitrooxodihydro triazolotriazinide

Composition

1 capsule contains:

The active substance: Riamilovir (TRIAZAVIRIN®) – 250 mg,

Excipients: Calcium stearate – 2 mg.

The weight of the capsule contents is 252 mg.

Capsule shell composition:

• Capsule (housing) № 1: titanium dioxide (E171), quinoline yellow dye (E104), sunset yellow dye (E110), medical gelatin.
• Capsule (cap) № 1: titanium dioxide (E171), colorant azorubin (E122), gelatin, medical.
• Capsule weight with contents – 328 mg.

.

How to take, the dosage

Triazavirin® is taken orally with plenty of drinking water, regardless of meals. The capsule should be swallowed whole; it is not recommended to chew, crush the capsule.

The drug should be started not later than the 2nd day from the beginning of the disease (manifestation of clinical symptoms of influenza and other acute respiratory viral infections).

Recommended dose:

in influenza and other acute respiratory viral infections: On 1 capsule (250 mg)
3 times daily for 5 consecutive days.

Maximal single dose: 1 capsule (250 mg). Maximum daily dose: 3 capsules (750 mg).

If for 5 days there is no improvement or worsening of symptoms or if new symptoms develop, you should talk to your doctor. Use only according to the indication, route of administration, and dosage listed in the directions.

Interaction

Special clinical trials to study the interaction with other medicinal products have not been conducted. If you use any medicines (including over-the-counter ones), consult your doctor before using the medicinal product TRIAZAVIRIN®.

Special Instructions

The drug TRIAZAVIRIN^® contains the dyes sunset yellow (E110) and azorubin (E122), which may cause allergic reactions.

Influence on driving, operating machinery

Have not been studied, but based on the spectrum of adverse reactions, no effect on these activities is expected.

Synopsis

Solid gelatin capsules size #1, yellow body and red cap. The contents of the capsules are fine crystalline powder or pellets of yellow or yellow-green color.

Contraindications

– Hypersensitivity to the drug components;
– Pregnancy;
– Breast-feeding period;
– Children under 18 years of age (effectiveness and safety have not been determined);
– Renal/liver failure (effectiveness and safety have not been determined).

Side effects

Disorders of the blood and lymphatic system: increased number of eosinophils in the blood.

Disorders of the immune system: allergic reactions (rash).

Nervous system disorders: headache.

Gastrointestinal tract disorders: dyspeptic phenomena (nausea, vomiting, bloating, pasty stools, flatulence, heartburn, abdominal pain, diarrhea, dry mouth).

Renal and urinary tract disorders: increase in urine red blood cells, white blood cells, squamous epithelium, presence of bacteria in the urine.

Laboratory and instrumental findings: Elevated plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels.

General disorders and reactions at the site of administration: Sweakness.

If you experience or worsen the side effects listed in the instructions, or if you notice any other side effects not listed in the instructions, tell your doctor.

Overdose

Symptoms:nausea, vomiting, dyspeptic disorders, stomach pain.

Treatment:symptomatic therapy. If these symptoms occur, it is necessary to stop taking the drug and consult a physician.

Treatment:Symptomatic therapy.

Pregnancy use

Due to lack of strictly controlled studies in humans, the drug administration during pregnancy is contraindicated (see section “Contraindications”). Administration of the drug during breastfeeding has not been studied, therefore, if it is necessary to use the drug during lactation, breastfeeding should be stopped.